Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
TTBK2 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, E |
|---|---|
| Primary Accession | Q6IQ55 |
| Other Accession | AAH71556, 47940064 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | 137412 Da |
| Application Notes | TTBK2 antibody can be used for detection of TTBK2 by immunohistochemistry at 5 µg/mL. |
| Gene ID | 146057 |
|---|---|
| Target/Specificity | TTBK2; TTBK2 antibody is human specific. At least four isoforms of TTBK2 are known to exist; this antibody will detect only the two largest isoforms. |
| Reconstitution & Storage | TTBK2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | TTBK2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | TTBK2 |
|---|---|
| Synonyms | KIAA0847 |
| Function | Serine/threonine kinase that acts as a key regulator of ciliogenesis: controls the initiation of ciliogenesis by binding to the distal end of the basal body and promoting the removal of CCP110, which caps the mother centriole, leading to the recruitment of IFT proteins, which build the ciliary axoneme. Has some substrate preference for proteins that are already phosphorylated on a Tyr residue at the +2 position relative to the phosphorylation site. Able to phosphorylate tau on serines in vitro (PubMed:23141541). Phosphorylates MPHOSPH9 which promotes its ubiquitination and proteasomal degradation, loss of MPHOSPH9 facilitates the removal of the CP110-CEP97 complex (a negative regulator of ciliogenesis) from the mother centrioles, promoting the initiation of ciliogenesis (PubMed:30375385). Required for recruitment of CPLANE2 and INTU to the mother centriole (By similarity). |
| Cellular Location | Cell projection, cilium. Cytoplasm, cytoskeleton, cilium basal body. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole. Cytoplasm, cytosol. Nucleus Note=Localizes at the transition zone, a region between the basal body and the ciliary axoneme (PubMed:23141541). May also be present in cytosol and, at lower level in the nucleus (PubMed:21548880) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
TTBK2 Antibody: Tau tubulin kinase (TTBK2) is a serine/threonine kinase whose substrates are thought to include the tau and tubulin proteins. Mutations in the TTBK2 gene cause spinocerebellar ataxia type 11 (SCA11), a neurodegenerative disease characterized by progressive ataxia and atrophy of the cerebellum and brainstem. Recent studies have shown that increased levels of TTBK2 expression in kidney carcinoma and melanoma cell lines increases resistance to the chemotherapeutic agent Sunitinib, and that reduction of TTBK2 though the use of siRNA sensitized these cell lines to the effects of Sunitib, suggesting that TTBK2 can be used as a resistance marker as well a potential target to overcome resistance.
References
Kitano-Takahashi M, Morita H, Kondo S, et al. Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2007; 63:602-4.
Edener U, Kurth I, Meiner A, et al. Missense exchanges in the TTBK2 gene mutated in SCA11. J. Neurol. 2009; 1856-9.
Bender C and Ullrich A. PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma cell lines. Int. J. Cancer 2011; epub.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
